Method of treating and preventing premature birth

FIELD: obstetrics and gynecology.

SUBSTANCE: over a 2-5 day period, 2.0 ml of Ginipral is administered once a day intravenously in a drop-by-drop manner followed by intravenously drop-by-drop administered 30-40 min later 2.0 ml of Instenone and, in the evening, 1 dragee Instenone orally. Afterwards, Instenone and Ginipral are administered orally: the former in dose of 1 dragee thrice a day with meal and the latter in dose of 1 pellet four times a day after meal until symptoms of the risk of prevention of pregnancy disappear.

EFFECT: prolonged pregnancy and prevented premature birth, which favors reduced irritation, normalized tonus, contractive activity of uterus, and improved psychic and emotional state of women.

2 ex

 

The invention relates to medicine, obstetrics, and in particular to methods for treatment and prevention of preterm birth, and can be used in clinical practice.

Prematurity and preterm birth (before 37 weeks of pregnancy) are causes of perinatal morbidity and mortality. PTD is stable and is 5-12%. An important aspect of the problem that worsens the condition of the fetus and increases the number of adverse outcomes in children.

Beta-adrenoceptor agonist currently occupy one of the first places in the prevention and therapy of pregnancy, use of psychopharmacological substances, derivatives of benzodiazepine, fenotiazina, antispasmodic, N-cholinolytic, ganglioblokatory; isoptin, ethanol, verapamil (Art, Oviplokos Adrenergic funds in obstetric practice. 2000, p.110-115). For the prototype accepted method for the treatment and prevention of preterm birth with the appointment of ginipral (Art, Oviplokos Adrenergic funds in obstetric practice. 2000, str-199), one of the most safe and effective means possessing high selectivity for beta-adrenergic receptors of the myometrium, no side effects, low permeability of the drug through the placental barrier. At the same the time has a relatively short effective, in consequence developed by desensitization Beth receptors in the myometrium to the specified tool.

Goal - increasing the period of prolongation of pregnancy, prevention of premature birth.

In the proposed method of treatment and prevention of preterm birth, including the appointment of ginipral goal is achieved by the fact that within 2-5 days injected intravenously at 1 in the morning every day ginipral 2.0 ml for 6-8-10 drops per minute, after 30-40 minutes, enter instenon intravenous drip of 2.0 ml 10-40 drops per minute, and in the evening 1 tablet of instenon, and then continue to receive instenon 1 pill 3 times a day during meals, reception ginipral 1 tablet 4 times a day after meals until disappearance of symptoms of threatened abortion.

Especially shown should be considered as the combined use of instenon and ginipral when expressed degrees of threatened abortion.

Ginipral is a beta-2-sympathomimetic, active substance - hexoprenaline relaxes uterine musculature: reduces the frequency and intensity of contractions, due to the action of B2-adrenergic receptors in the uterus, at the same time causes an improvement in the condition of the fetus due to changes in fetoplacental complex, has a beneficial effect on uteroplacental circulation, facilitating the formation of surfactant and more is to slow the maturation of the fetal lung, what is an effective method of prevention of hyaline membranes, if the child is born premature, and, in addition ginipral increases the weight of the fruit.

Instenon is a combination drug consisting of 3 vasoactive substances and metabolically active properties (etofillin, hexobendine, etamivan), due to the pharmacological effects which instenon has tokoliticheskoe action, causes the activation of the limbic-hypothalamo-reticular complex of the brain and improves circulation in the functional system "mother-placenta-fetus", thus affecting different stages of pathogenesis of this obstetric pathology.

The proposed method for the prevention and treatment carried out by the following procedure: ginipral 2.0 ml (1 ampoule) is dissolved in 400 ml of 5% glucose. The solution ginipral injected intravenously, 1 time a day. The rate of infusion sets for every pregnant individually with consideration of uterine activity, 6-8-10 drops per minute. Infusion spend 3-5 days (depending on the severity of threatened abortion). In a further move only on oral ginipral 1 tablet 4-6 times a day after meals (squeezed a small amount of water).

2.0 ml of instenon (1 ampoule) is dissolved in 200 ml of isotonic NaCl. The solution instenon give/drip in 1 time a day, che is ez 30-40 minutes after administration ginipral. The rate of intravenous administration sets for every pregnant individually with consideration of uterine activity, starting with 10 drops per minute every 20 minutes, a speed of up to 10 drops, to a maximum of 40 drops per minute. Infusion spend 3-5 days (depending on the severity of threatened abortion). The evening of the day intravenous instenon, appoint 1 pills drugs inside, later transferred only to the oral ingestion of instenon 1 pill 3 times a day during or after a meal (not liquid, with a small amount of water).

Previously in animal models of preterm birth we have studied the effects ginipral and instenon and their combination with successive introduction ginipral and instenon on the bioelectric potentials of the myometrium of pregnant rats in different series of experiments. The experiments performed on 40 white Mature pregnant rats line Wister. Doses are calculated so that they are adequate therapeutic doses calculated per 1 kg of body weight of pregnant women. Instenon injected intraperitoneally at a dose of 0.1 ml per animal. Ginipral was introduced as intraperitoneally at a dose of 2.5 mcg/kg Executed 4 series of experiments.

As a result of the research showed that in the comparative experiments on the model of preterm birth in the us is the conditions of the entire organism shows what instenon inhibits the bioelectric activity of the myometrium in 10 minutes after injection. Tokoliticheskoe effect lasts 40 minutes. The restoration of the indicators of the amplitude and frequency of action potentials prior to baseline values comes at the 60th minute. Introduction ginipral (2.5 mg/kg) leads to the inhibition of bioelectric activity after 10 minutes, and the inhibition of the amplitude continues for 30 minutes, the frequency - 40 minutes. Thus tokoliticheskoe effect ginipral slightly inferior to the duration of the instenon. In experiments on pregnant rats on the model of preterm birth is shown that the sequential introduction of instenon and ginipral (30 minutes) in the same doses provides a longer (60 minutes) and expressed tokoliticheskoe effect in the experiment. The effect is explained by the different mechanisms of inhibitory action of instenon and ginipral in the myometrium of pregnant women.

The use of this combination in the clinic 75 pregnant women with threatening preterm delivery in the form of an acute Togolese, also shows a more pronounced and prolonged effect on uterine activity. No identified negative effects of these drugs on the body of a pregnant woman, fetus and newborn according to the clinic, child assessment on Apgar scale, the data machine, ultrasound abnormal Doppler waveforms and ultrasonic determine the condition of the cervix. The proposed method were treated at 75 pregnant, which was the main group. The control group included more than 100 pregnant women, the treatment which was carried out in the traditional way. Groups surveyed did not differ among themselves in terms of age groups, family history of somatic and obstetric background.

The use of instenon in combination with ginipral for the prevention and treatment of preterm birth has led to reduced excitability, normalize tone and contractile activity of the uterus and improves mental and emotional state in the vast majority of women. The effectiveness of combinations of these drugs according to the clinic was 93%.

When cardiotocographic study during therapy instenon and ginipral found that the introduction of drugs led to statistically significant improvement of key indicators of cardiotocogram, kharakterizuyuschikh the fetus (amplitude oscillations, myocardial reflex, the number of perturbations of fruit per 30 minutes).

Thus, the proposed new pathogenetically grounded method for the prevention and treatment of preterm birth by a combination of instenon and ginipral can be recommended for use in obstetric hospitals, leading to increased therapeutic effect of treatment Yes the Noah obstetric pathology due to the normalization of the contractile activity of the uterus and emotional state of patients, to reduce complications in the newborn.

The claimed method of treatment can be demonstrated by the following examples:

Example 1.

Avtomobilnaya perforada P., 28 (history No. 5515), he enrolled in the Institute of obstetrics and gynecology. Otto RAMS 10.12.03.

Diagnosis: Pregnancy 34 weeks. Threatening preterm delivery.

On admission the woman complained of nagging pain in the lower abdomen, in the lumbar region.

Objective: Pregnant in satisfactory condition. The uterus on palpation painless, in a normal tone, excitable palpation. Slated to be actually the head of the fetus is movable above the entrance to the pelvis. The fetal heart beat is clear, rhythmic, 140 beats per minute.

Data inspection PV: cervix length 1.5 cm, softened, centered, is passable for one finger for internal Zev. SAC a whole, are slated to be actually the head of the fetus is movable above the entrance to the pelvis. The Cape is not achievable. The deformation of the bones of the pelvis not.

The results of tomographie: registered irregular, varying in intensity and duration of uterine contractions.

Treatment:

Ginipral 2.0 ml, 400 ml of 5% glucose intravenous infusion at a rate of 6-8-10 drops per minute, 1 per day. After 30-40 minutes after injection ginipral/drip, instenon 2.0 ml 200 ml of physiological solution, with a speed of 10 to 40 drops per minute, 1 time per day is in the morning, evening - reception 1 jar of instenon inside. Duration of therapy 3 days.

On the background of therapy on the basis of subjective sensations pregnant and data tomographie contractile activity of the uterus is normalized. Data vaginal research 13.12.03 cervix length of 1.5 cm, centered, softened, runs for 1 finger for internal Zev. SAC a whole. The head is movable above the entrance to the pelvis.

In connection with the effect of normalization of contractile activity of the uterus, infusion therapy is finished, the ginipral appointed 1 tablet × 4 times a day inside, instenon 1 bean × 3 times a day inside (took drugs within 7 days).

The patient was discharged with progressing pregnancy.

Example 2.

Avtomobilnaya, powerseraya. S., 23 years (history No. 5513), he enrolled in the Institute of obstetrics and gynecology. Doota RAMS 10.12.03.

Diagnosis: Pregnancy 34 weeks. The conflict AVO 1:256 (5.12.03). Chronic pyelonephritis without exacerbation. Threatening preterm delivery.

On admission the woman complained of General weakness, dragging pain in the abdomen, in the lumbar region.

Objective: Pregnant in satisfactory condition. The uterus on palpation painless, in a normal tone, excitable palpation. Slated to be actually the fetus's head, moving over whodo is in the pelvis. The fetal heart beat is clear, rhythmic, 142 beats per minute.

Data inspection PV: cervix length up to 2 cm, softened at the edges, sealed in the field of internal throat, rejected, left, diameter of the cervical canal 1,5 see the Fetal bladder is intact, slated to be actually the head of the fetus is movable above the entrance to the pelvis. The Cape is not achievable. The deformation of the bones of the pelvis not.

The results of tomographie: registered irregular, varying in intensity and duration of uterine contractions.

Treatment:

Ginipral 2.0 ml, 400 ml of 5% glucose intravenous infusion at a rate of 6-8-10 drops per minute, 1 per day. After 30-40 minutes after injection ginipral/drip instenon 2.0 ml 200 ml of physiological solution, with a speed of 10 to 40 drops per minute, 1 times a day, morning, evening reception 1 jar of instenon inside. Duration of therapy 2 days.

On the background of therapy on the basis of subjective sensations pregnant and data tomographie contractile activity of the uterus is normalized. Data vaginal research 12.12.03 without negative dynamics.

In connection with the effect of normalization of contractile activity of the uterus, infusion therapy is finished. Ginipral appointed 1 tablet × 4 times a day inside, instenon 1 bean × 3 times a day inside (took drugs for 5 days).

The patient was discharged from the program is serouse pregnancy.

Method for the treatment and prevention of premature birth by assigning ginipral, characterized in that within 2-5 days 1 time per day enter ginipral 2.0 ml intravenous drip, after 30-40 minutes, enter instenon 2.0 ml intravenous drip, and in the evening 1 tablet of instenon, and then continue to receive only oral instenon 1 pill 3 times a day during meals and receive ginipral 1 tablet 4 times a day after meals until disappearance of symptoms of threatened abortion.



 

Same patents:

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to new derivatives of pyrrolopyrimidine of the formula (1) and their pharmaceutically acceptable salts possessing properties of selective inhibitor of specific cyclic guanosine 3',5'-monophosphate phosphodiesterase (specific cGMP PDE) (PDE V). In the formula (1) R1 represents hydrogen atom (H), (C1-C3)-alkyl substituted optionally with one or some fluorine atoms; R2 represents H, halogen atom, (C1-C6)-alkyl substituted optionally with hydroxyl group (-OH), (C1-C3)-alkoxy-group, (C3-C6)-cycloalkyl or one or some fluorine atoms, (C3-C6)-cycloalkyl; R3 represents (C1-C6)-alkyl substituted optionally with (C3-C6)-cycloalkyl or one or some fluorine atoms; R4 represents (C1-C6)-alkyl substituted optionally with one or some fluorine atoms; R5 represents -SO2NR6R, -NHSO2R8 or heterocyclyl such as tetrazolyl; each R6 and R7 represents independently H or (C1-C6)-alkyl substituted optionally with -CO2H or one or some fluorine atoms; or in common with nitrogen atom to which they are bound form monocylic ring, such as imidazole, pyrrolidine, piperidine, morpholine, piperazine and homopiperazine wherein indicated group is replaced optionally with R9 wherein R9 represents (C1-C6)-alkyl substituted optionally with one or some halogen atoms, hydroxyl group (OH), (C1-C3)-alkoxy-group that is replaced optionally with one or some fluorine atoms, -NR11R12, -C=NR13(NR14R15) or tetrazolyl group, 6-membered nitrogen-containing heteroaryl group; each R11 and R12 represents independently H or (C1-C4)-alkyl; R13represents H; each R14 and R15 represents independently H. Also, invention relates to intermediate compounds, methods for preparing compounds and pharmaceutical compositions. Proposed compounds can be used in treatment of impotency, sexual dysfunction in females, stable, nonstable and variant (Prinzmental) stenocardia and other diseases also.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

15 cl, 1 tbl, 250 ex

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to new derivatives of pyrrolopyrimidine of the formula (1) and their pharmaceutically acceptable salts possessing properties of selective inhibitor of specific cyclic guanosine 3',5'-monophosphate phosphodiesterase (specific cGMP PDE) (PDE V). In the formula (1) R1 represents hydrogen atom (H), (C1-C3)-alkyl substituted optionally with one or some fluorine atoms; R2 represents H, halogen atom, (C1-C6)-alkyl substituted optionally with hydroxyl group (-OH), (C1-C3)-alkoxy-group, (C3-C6)-cycloalkyl or one or some fluorine atoms, (C3-C6)-cycloalkyl; R3 represents (C1-C6)-alkyl substituted optionally with (C3-C6)-cycloalkyl or one or some fluorine atoms; R4 represents (C1-C6)-alkyl substituted optionally with one or some fluorine atoms; R5 represents -SO2NR6R, -NHSO2R8 or heterocyclyl such as tetrazolyl; each R6 and R7 represents independently H or (C1-C6)-alkyl substituted optionally with -CO2H or one or some fluorine atoms; or in common with nitrogen atom to which they are bound form monocylic ring, such as imidazole, pyrrolidine, piperidine, morpholine, piperazine and homopiperazine wherein indicated group is replaced optionally with R9 wherein R9 represents (C1-C6)-alkyl substituted optionally with one or some halogen atoms, hydroxyl group (OH), (C1-C3)-alkoxy-group that is replaced optionally with one or some fluorine atoms, -NR11R12, -C=NR13(NR14R15) or tetrazolyl group, 6-membered nitrogen-containing heteroaryl group; each R11 and R12 represents independently H or (C1-C4)-alkyl; R13represents H; each R14 and R15 represents independently H. Also, invention relates to intermediate compounds, methods for preparing compounds and pharmaceutical compositions. Proposed compounds can be used in treatment of impotency, sexual dysfunction in females, stable, nonstable and variant (Prinzmental) stenocardia and other diseases also.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

15 cl, 1 tbl, 250 ex

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to new derivatives of pyrrolopyrimidine of the formula (1) and their pharmaceutically acceptable salts possessing properties of selective inhibitor of specific cyclic guanosine 3',5'-monophosphate phosphodiesterase (specific cGMP PDE) (PDE V). In the formula (1) R1 represents hydrogen atom (H), (C1-C3)-alkyl substituted optionally with one or some fluorine atoms; R2 represents H, halogen atom, (C1-C6)-alkyl substituted optionally with hydroxyl group (-OH), (C1-C3)-alkoxy-group, (C3-C6)-cycloalkyl or one or some fluorine atoms, (C3-C6)-cycloalkyl; R3 represents (C1-C6)-alkyl substituted optionally with (C3-C6)-cycloalkyl or one or some fluorine atoms; R4 represents (C1-C6)-alkyl substituted optionally with one or some fluorine atoms; R5 represents -SO2NR6R, -NHSO2R8 or heterocyclyl such as tetrazolyl; each R6 and R7 represents independently H or (C1-C6)-alkyl substituted optionally with -CO2H or one or some fluorine atoms; or in common with nitrogen atom to which they are bound form monocylic ring, such as imidazole, pyrrolidine, piperidine, morpholine, piperazine and homopiperazine wherein indicated group is replaced optionally with R9 wherein R9 represents (C1-C6)-alkyl substituted optionally with one or some halogen atoms, hydroxyl group (OH), (C1-C3)-alkoxy-group that is replaced optionally with one or some fluorine atoms, -NR11R12, -C=NR13(NR14R15) or tetrazolyl group, 6-membered nitrogen-containing heteroaryl group; each R11 and R12 represents independently H or (C1-C4)-alkyl; R13represents H; each R14 and R15 represents independently H. Also, invention relates to intermediate compounds, methods for preparing compounds and pharmaceutical compositions. Proposed compounds can be used in treatment of impotency, sexual dysfunction in females, stable, nonstable and variant (Prinzmental) stenocardia and other diseases also.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

15 cl, 1 tbl, 250 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with composition for fertilization in vitro and the system for its delivering (device). The composition suggested contains steroid at the quantity of below 5% (weight/weight), that is: 4.4-dimethyl-5α-cholesta-8.14.24-trien-3β-ol, hemisuccinate of 4.4-dimethyl-5α-cholest-8.14.24-trien-3β-ol; 5α-cholest-8.14-dien-3β-ol; hemisuccinate of 5α-cholest-8.14-dien-3β-ol; (20S)-cholest-5-en-3, 20-diol; N-(methionine)amide of 3β-hydroxy-4.4-dimethyl-5α-chol-8.14-dien-24-oic acid or cholest-5-en-16β-ol, and, also, additive (water-soluble protein or phosphoglyceride). Delivering system has got either one foramen or one cavity that contains the composition mentioned as a solid product or solution. The composition of sterols contains no constituents negatively affecting oocytes and could be dissolved in aqueous medium without physical impact (that is, heating, mixing or ultrasound treatment).

EFFECT: higher efficiency of fertilization in vitro.

8 cl, 5 ex, 3 tbl

FIELD: medicine, phytotherapy, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to using Belamcanda chinensis extract for preparing organ-selective medicinal preparation without uterotropic effect or with minimal such effect that is used as estrogen-like preparation. This preparation is used in selective treatment and/or prophylaxis of cardiovascular diseases, in particular, atherosclerosis and osteoporosis, climacteric disturbances, especially for prophylaxis or softening congestions of blood. Extract is used in manufacturing a medicinal preparation in ready formulation for selective treatment and/or prophylaxis of cardiovascular diseases, in particular atherosclerosis, and for selective treatment and/or prophylaxis of osteoporosis, climacteric disturbances, especially for prophylaxis and softening congestions of blood. Extract promotes to effective prophylaxis and/or treatment of cardiovascular diseases, in particular, atherosclerosis, climacteric disturbances, especially for prophylaxis and softening congestions of blood.

EFFECT: valuable medicinal properties of extract.

4 cl, 4 ex

FIELD: organic chemistry, medicine, biochemistry, pharmacy.

SUBSTANCE: invention relates to 2-aminomethylthieno[2,3-d]pyrimidines of the general formula (I): wherein R1 and R2 in common with C-atoms with which they are bound form 5-7-membered monounsubstituted cycloalkenyl ring; R3 and R4 are similar or different and represent independently of one another (C1-C8)-alkoxy-group or halogen atom; R5 and R6 can be similar or different and represent independently of one another hydrogen atom, linear or branched (C1-C8)-alkyl group that can be substituted with one or more hydroxyl, (C1-C8)-alkoxy-group, amine, mono-(C1-C8-alkyl)-amine or di-(C1-C8-alkyl)-amine groups, or in common with nitrogen atom to which they are bound form a heterocyclic ring that comprises optionally one or more additional nitrogen atoms and substituted with one or more hydroxyl, (C1-C8)-alkoxy- or (C1-C8)-alkylol groups. Compounds elicit the inhibitory effect with respect to activity of phosphodiesterase V and can be used in treatment of cardiovascular system states and in disturbance in the potency injury. Also, invention describes a medicinal preparation based on compounds said, a method for its preparing and a method for preparing compounds.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of compounds.

6 cl, 1 tbl, 16 ex

FIELD: medicine, gynecology, pharmacy.

SUBSTANCE: invention proposes using pimafucin (natamycin) as agent for treatment of bacterial vaginitis. Method for treatment of bacterial vaginitis involves intravaginal administration of pimafucin as 2% cream, 2 times per a day in morning and evening for 7-10 days and for first 3 days pimafucin-containing vaginal suppository in the dose 100 mg is administrated additionally in evening after administration of cream into vagina. Invention provides high effectiveness of treatment and clinical-etiological recovery in 92.3% of cases being without prescription of medicinal preparations. Method has no contraindications and can be used in all period of pregnancy and without adverse effects.

EFFECT: improved treatment method, enhanced effectiveness of agent and treatment.

2 cl, 1 ex

FIELD: medicine, obstetrics.

SUBSTANCE: invention relates to a method for treatment of delivery activity weakness. Method involves simultaneous administration of prostaglandin F in the concentration 12.5 mcg/ml at the rate 8 mcg/min and adenosine triphosphate sodium in the concentration 0.25 mcg/ml at the rate 0.25 mcg/min. Infusion continues up to end of the second stage of delivery. Method provides enhancing the delivery activity, increasing rate of uterine orifice opening on the background of the reduced dose of prostaglandin.

EFFECT: improved treatment method.

3 ex

FIELD: medicine, gynecology, pharmacy.

SUBSTANCE: invention relates to a method for supporting amenorrhea in women subjecting the constant progestin therapy providing to induce endometrial atrophy and to avoid significant unfavorable adverse effects that accompanying administration of progesin usually. Invention provides the complete amenorrhea without intermittent bleeding or secretion of small blood amount from vagina and without significant unfavorable adverse effects as can be occur in other methods. The curative effect is attained due to the constant intravaginal administration of progestin in water-insoluble, water-swelling cross-linked polymer based on polycarboxylic acid.

EFFECT: improved supporting method, valuable medicinal properties of composition.

7 cl, 3 dwg, 2 ex

FIELD: medicine, gynecology, pharmacy.

SUBSTANCE: invention relates to a method for supporting amenorrhea in women subjecting the constant progestin therapy providing to induce endometrial atrophy and to avoid significant unfavorable adverse effects that accompanying administration of progesin usually. Invention provides the complete amenorrhea without intermittent bleeding or secretion of small blood amount from vagina and without significant unfavorable adverse effects as can be occur in other methods. The curative effect is attained due to the constant intravaginal administration of progestin in water-insoluble, water-swelling cross-linked polymer based on polycarboxylic acid.

EFFECT: improved supporting method, valuable medicinal properties of composition.

7 cl, 3 dwg, 2 ex

FIELD: veterinary science.

SUBSTANCE: one should introduce endovit complex preparation once daily for dogs. Moreover, during the first 5 d endovit should be introduced at the dosage of 30 mg/kg, during the next 10 d - 25 mg/kg and during the last 5 d 20 mg/kg body weight. The suggested innovation provides normalization of myocardial trophic nature, interrupts dystrophic processes in it, improves functional state of cardiac conductory system and, thus, provides the chance to treat both the main and secondary disease by the mentioned scheme without applying any additional cardiological remedies.

EFFECT: higher efficiency of therapy.

1 tbl

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention describes derivatives of 8-phenyl-6,9-dihydro[1,2,4]-triazolo[3,4-I]purine-5-one of the general formula:

wherein R1 means hydrogen atom, group -CH2-R6 wherein R6 means phenyl; R2 means (C1-C5)-alkyl or group -(CH2)n-R6 wherein n= 1 or 2; R6 means (C1-C4)-alkoxy-group or pyridyl group; R3 means (C1-C6)-alkyl; R4 means hydrogen atom or (C1-C4)-alkyl; R5 means -(CH2)n-R7 wherein n = 0-4; R7 means 3-7-membered ring comprising 1-3 heteroatoms taken among nitrogen atom (N) and oxygen atom (O), (C3-C7)-cycloalkyl or phenyl wherein indicated groups can be substituted with different substitutes; or R4 and R5 mean independently hydrogen atom (H), (C2-C6)-alkynyl or (C1-C6)-alkyl that can be substituted possibly; or R4 and R5 in common with nitrogen atom (N) form 4-7-membered ring comprising 1-2 heteroatoms taken among N and O and substituted possibly. Also, invention relates to their pharmaceutically acceptable salts, methods for preparing these compounds, intermediate substances, pharmaceutical composition and a to a method for treatment of different diseases mediated by activity of phosphodiesterase-5 (PDE-5). Described compounds of the formula (I) are inhibitor of PDE-5.

EFFECT: improved preparing method and treatment, valuable properties of compounds.

20 cl, 5 tbl, 149 ex

FIELD: veterinary science.

SUBSTANCE: about 20-25 d before calving one should introduce intramuscularly 0.5%-sodium selenite solution for cows at the dosage of 10 ml. Twice before and twice after calving at 10-d-long interval - tetravit at the dosage of 10 ml at the content of 50000 IU vitamin A, 25000 IU vitamin D, 20 mg vitamin E and 5 mg vitamin F per 1 ml. Succinic acid should be introduced 20-25 d both before and after calving at the dosage of 1.0 g. The method provides efficient correction of the main values of homeostasis in cows after calving.

EFFECT: higher efficiency of normalization.

2 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with antiviral preparations that contain aliphatic alcohol C21-C28 in combination with either nucleoside or nucleotide analog or phosphoformic acid in pharmaceutically acceptable carrier. It is necessary to mention that n-docosanol is considered to be a preferable aliphatic alcohol. Concentration of aliphatic alcohol C21-C28 corresponds to 0.05% to 40% by weight. Concentration of either nucleoside or nucleotide analog or phosphoformic acid corresponds to 0.1% to 10% by weight. The innovation, also, deals with the ways to treat viral infections due to applying such compositions. Aliphatic alcohols C21-C28 synergistically intensify antiviral activity of nucleoside analogs directed against replication of several herpetic viruses and that of cow's pox.

EFFECT: higher efficiency of inhibition.

28 cl, 13 dwg, 21 ex, 6 tbl

FIELD: organic chemistry, biochemistry, biology.

SUBSTANCE: invention relates to a pharmaceutical composition eliciting the inhibitory effect on activity of serine protease (caspase-3) in the form of tablet, capsule or injections placed into acceptable package, to a method for its preparing and a method for treatment of diseases associated with enhanced activation of apoptosis. The composition comprises compound 2,3-dihydro-1H-benzo[g]pteridine-4-one of the general formula (1) (1)

or its salt with pharmacologically acceptable acid as an active component taken in pharmaceutically effective amount wherein X means oxygen (O) or sulfur (S) atom; R1 and R2 represent independently of one another hydrogen atom, inert substitute taken among the group including low- or non-reactive and optionally substituted radical, such as (C1-C7)-alkyl, (C2-C7)-alkenyl, (C2-C7)-alkynyl, (C1-C7)-alkoxy-group, (C7-C12)-aralkyl, (C7-C12)-heterocyclylalkyl, (C7-C12)-alkaryl, (C3-C10)-cycloalkyl, (C3-C10)-cycloalkenyl, phenyl, aryl, heterocyclyl; optionally substituted hydroxy-(C1-C5)-alkyl group; R3, R4, R5 and R6 represent independently of one another hydrogen, halogen atom, -CF3, -CN, inert substitute taking among the group including low- or non-reactive and optionally substituted radical, optionally substituted hydroxyl group, optionally substituted hydroxy-(C1-C5)-alkyl group, optionally substituted amino-group, optionally substituted amino-(C1-C7)-alkyl group, optionally substituted carboxy-(C1-C7)-alkyl group, optionally substituted (C1-C6)-alkylcarboxy-(C1-C6)-alkyl group, optionally substituted carbamoyl group, optionally substituted (C1-C6)-alkylcarbamoyl group, optionally substituted sulfamoyl group. Also, invention relates to applying compounds of the formula (1) for preparing pharmaceutical composition and experimental study (in vitro and in vivo) processes associated with apoptosis.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of composition.

7 cl, 1 dwg, 2 tbl, 5 ex

FIELD: organic chemistry, heterocyclic compounds, biochemistry.

SUBSTANCE: invention relates to new compounds - purine derivatives of the general formula (I): in free form or salt wherein X means oxygen or sulfur atom or group NR5; R1 means alkyl, alkenyl, cycloalkyl, benzocycloalkyl, cycloalkylalkyl or aralkyl group that can be substituted optionally with hydroxy-, carboxy-group or alkoxycarbonyl; or if X means NR5 then R1 can mean alternatively heterocyclic group taken among benzylpiperidyl or the formula: ; or group of the formula (II): ; R2 means hydrogen atom, alkyl or alkoxy-group; R3 means hydrogen atom, alkoxy-, carboxy-group, carboxyalkyl, alkoxycarbonyl, -N(R9)R10, (C1-C4)-alkylene-SO2N(R11)R12 or -CON(R13)R14; or if two substitutes R2 and R3 are joined to adjacent carbon atoms in indicated benzene ring then in common with carbon atoms to which they are joined they mean heterocyclic group comprising 5-10 ring atoms among them one or two atoms mean heteroatoms taken among nitrogen, oxygen and sulfur atom; R4 means hydrogen atom, alkoxy-, carboxy-group, carboxyalkyl, -SO2N(R11)R12, -N(R9)R10 or -CON(R13)R14; or if two substitutes R3 and R4 are joined to adjacent carbon atoms in indicated benzene ring then in common with carbon atoms to which they are joined they mean heterocyclic group comprising 5-6 ring atoms among them one or two atoms mean heteroatoms taken among nitrogen, oxygen or sulfur atom; R5 means hydrogen atom or alkyl; R6, R7 and R8 mean hydrogen atom, or one of these radicals means -SO2NH2, -N(CH3)COCH3, -CONH2 and two others mean hydrogen atom; R9 means hydrogen atom or alkyl; R10 means hydrogen atom, -COR15 wherein R15 means alkyl, alkoxy-group; or R9 and R10 in common with nitrogen atom to which they are joined mean heterocyclic group comprising 5 or 6 ring atoms among them one or two atoms mean heteroatoms taken among nitrogen and oxygen atom; R11 means hydrogen atom or alkyl; R12 means hydrogen atom, alkyl, hydroxyalkyl, carboxyalkyl or alkoxycarbonylalkyl; or R11 and R12 in common with nitrogen atom to which they are joined mean heterocyclic group comprising 5 or 6 ring atoms among them one or two atoms mean heteroatoms taken among nitrogen and oxygen atom; R13 and R14 each and independently of one another means hydrogen atom or alkyl with exception of 2-(para-n-butylanilino)-6-methoxypurine, 2-(para-n-butylanilino)-6-(methylthio)purine, 2,6-di-(phenylamino)-purine, 2,6-di-(para-tolylamino)-purine and 2-(para-tolylamino)-6-(phenylamino)-purine.

EFFECT: valuable biochemical properties of compounds.

11 cl, 4 tbl, 221 ex

FIELD: pharmaceuticals.

SUBSTANCE: invention provides topical blood circulation improving remedy containing simultaneously nitroglycerine and aminophylline. Remedy can be provided in the form of emulsion, gel, or ointment, which are administered 1-2 times a day.

EFFECT: strengthened blood circulation activation effect, which is prolonged to 24 hours.

5 cl, 9 ex

The invention relates to the pharmaceutical industry, in particular the production of medicines used for colds, relieving headaches and neuralgia
The invention relates to medicine, namely to pharmacy
The invention relates to medicine, gynecology, and can be used for the treatment of primary dysmenorrhea

FIELD: organic chemistry, medicine.

SUBSTANCE: invention reports about preparing new substituted derivatives of 2-dialkylaminoalkylbiphenyl of the general formula (I):

wherein n = 1 or 2; R1 means cyano-group (CN), nitro-group (NO2), SO2CH3, SO2CF3, NR6aR7a, acetyl or acetamidyl; R2 means hydrogen atom (H), fluorine atom (F), chlorine atom (Cl), bromine atom (Br), cyano-group (CN), nitro-group (NO2), CHO, SO2CH3, SO2CF3, OR6, NR6R7, (C1-C6)-alkyl, acetyl or acetamidyl being alkyl can comprise one or more similar or different substitutes taken among halogen atom or hydroxy-group; or R1 and R mean in common group -OCH2O, -OCH2CH2O, CH=CHO, CH=C(CH3)O or CH=CHNH; R3 means H, F, Cl, Br, CN, NO2, CHO, SO2CH3, SO2CF3, OR6, NR6R7, (C1-C6)-alkyl, acetyl or acetamidyl being alkyl can comprise one or more similar or different substitutes taken among halogen atom or hydroxy-group; R4 and R5 have similar or different values and mean hydrogen atom (H) or unsubstituted (C1-C6)-alkyl; R6 and R7 have similar or different values and mean hydrogen atom (H) or unsubstituted (C1-C6)-alkyl; R6a means hydrogen atom (H) or unsubstituted (C1-C6)-alkyl; R7a means unsubstituted (C1-C6)-alkyl as their bases and/or salts of physiologically acceptable acids, with exception of compound representing 4-chloro-2'-dimethylaminomethylbiphenyl-2-carbonitrile and to a method for their preparing. Derivatives of 2-dialkylaminoalkylbiphenyl can be used in medicine for treatment or prophylaxis of pains, inflammatory and allergic responses, depressions, narcomania, alcoholism, gastritis, diarrhea, enuresis, cardiovascular diseases, respiratory ways diseases, cough, psychiatry disorders and/or epilepsy.

EFFECT: valuable medicinal properties of compounds.

13 cl, 2 tbl, 43 ex

Up!